Kura Oncology, Inc. (KURA) Q3 2026 earnings results

Kura Oncology, Inc. (KURA) reported Q3 2026 results on Nov 10, 2026, 4:05:16 PM ET: GAAP EPS -$0.78 vs. -$0.81 expected (beat by 3.8%); revenue $22.84M vs. $23.89M expected (miss by 4.4%), according to Nexqual's capture of the SEC 8-K filing (nexqual.com/earnings/2026-11-10/KURA). Outlook: Kura updated its 2026 collaboration revenue guidance to $40 million to $45 million and maintains 2027 and 2028 guidance of $90 million to $110 million each.

KURA Q3 2026 results vs. estimates, Nexqual · nexqual.com/earnings/2026-11-10/KURA
MetricReportedAnalyst estimateResult
EPS (GAAP, diluted)-$0.78-$0.81Beat by 3.8%
Revenue$22.84M$23.89MMiss by 4.4%

Analyst estimate: the average forecast before the release.

Source

Figures from the SEC 8-K filing, released Nov 10, 2026, 4:05:16 PM ET. Nexqual published them 94 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.

Year over year

Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 10.1% from $20.75M; GAAP diluted EPS was -$0.78 vs. -$0.85 (+8.2%).

Stock reaction

The results came out after the market closed. KURA closed at $7.73 on November 11, 2026, up 2.1% from its $7.57 close on November 10, 2026 before the results. Latest: $7.34 (close, November 18, 2026), −3.0% since the pre-release close.

Questions and answers

Did Kura Oncology, Inc. beat earnings expectations?

Yes. Kura Oncology, Inc. reported GAAP EPS of -$0.78 against an average analyst estimate of -$0.81 (beat by 3.8%), and revenue of $22.84M against $23.89M expected (miss by 4.4%). Source: Nexqual (nexqual.com/earnings/2026-11-10/KURA).

What were Kura Oncology, Inc.'s Q3 2026 earnings and revenue?

GAAP diluted EPS of -$0.78 and revenue of $22.84M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 10.1% from $20.75M; GAAP diluted EPS was -$0.78 vs. -$0.85 (+8.2%). Source: Nexqual (nexqual.com/earnings/2026-11-10/KURA).

When did Kura Oncology, Inc. report Q3 2026 earnings?

Nov 10, 2026, 4:05:16 PM ET, in an SEC 8-K filing (Item 2.02). Source: Nexqual (nexqual.com/earnings/2026-11-10/KURA).

How did KURA stock react to the earnings?

The results came out after the market closed. KURA closed at $7.73 on November 11, 2026, up 2.1% from its $7.57 close on November 10, 2026 before the results. Latest: $7.34 (close, November 18, 2026), −3.0% since the pre-release close. Source: Nexqual (nexqual.com/earnings/2026-11-10/KURA).

What did Kura Oncology, Inc. say about its outlook?

Kura updated its 2026 collaboration revenue guidance to $40 million to $45 million and maintains 2027 and 2028 guidance of $90 million to $110 million each. Source: Nexqual (nexqual.com/earnings/2026-11-10/KURA).

More on KURA

KURA stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 10, 2026.

Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 18, 2026 at 21:05 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 18, 2026 at 21:05 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt